- Home
- NGD vs TFX Comparison
NGD vs TFX Comparison
Compare NGD & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGD | TFX |
|---|---|---|
| Founded | N/A | 1943 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | NGD | TFX |
|---|---|---|
| Price | $8.85 | $121.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 10 |
| Target Price | $8.75 | ★ $139.88 |
| AVG Volume (30 Days) | ★ 16.1M | 745.2K |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 1232.42 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | $1,242,200,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $62.14 | $9.90 |
| Revenue Next Year | $57.44 | $10.51 |
| P/E Ratio | $28.22 | ★ N/A |
| Revenue Growth | ★ 44.19 | 5.42 |
| 52 Week Low | $2.43 | $102.58 |
| 52 Week High | $9.59 | $185.94 |
Technical Indicators
Market Signals| Indicator | NGD | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 50.11 |
| Support Level | $8.68 | $120.77 |
| Resistance Level | $9.52 | $123.55 |
| Average True Range (ATR) | 0.51 | 3.40 |
| MACD | 0.03 | -0.48 |
| Stochastic Oscillator | 64.16 | 8.71 |
Price Performance
Historical ComparisonAbout NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.